AURELIA: A randomized phase III trial evaluating bevacizumab (BEV) plus chemotherapy (CT) for platinum (PT)-resistant recurrent ovarian cancer (OC).

2012136 citationsJournal Article

Authors

Éric Pujade-Lauraine · Délégation Paris 5

Felix Hilpert

B. Weber · Délégation Centre-Est

Alexander Reuß

Andrés Poveda · Fundación Instituto Valenciano de Oncología

Gunnar B. Kristensen · Norwegian Cancer Society

Roberto Sorio · Istituti di Ricovero e Cura a Carattere Scientifico

Ignace Vergote

Abstract

LBA5002^ The full, final text of this abstract will be available at abstract.asco.org at 12:01 AM (EDT) on Saturday, June 2, 2012, and in the Annual Meeting Proceedings online supplement to the June 20, 2012, issue of Journal of Clinical Oncology. Onsite at the Meeting, this abstract will be printed in the Saturday edition of ASCO Daily News.

Topics & Keywords

Ovarian cancer diagnosis and treatment

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Journal of Clinical Oncology

Volume 30, Issue 15_suppl, pp. LBA5002-LBA5002

DOI: 10.1200/jco.2012.30.15_suppl.lba5002

Field-Weighted Citation Impact: 33.13